Wall Street Zen upgraded Amgen Inc. (NASDAQ:AMGN) from hold to buy on June 14, 2026. The stock maintains a consensus hold rating with an average price target of $354.12.
Amgen exceeded first-quarter consensus estimates for both earnings per share and revenue. The company advanced its phase 3 trials for ABP 938, an eye-disease treatment. Clinical progress continues for the MARITIME-SWITCH obesity trial. These potential treatments serve as key future growth drivers for the biotechnology firm.